We give you a written timeline estimate for your case before you commit.Ask about treatment
Crohn's disease: US-approved treatments and how families in the Gulf can access them
A plain guide for families in the Gulf, checked against US FDA labels, US National Institutes of Health information, Gulf drug registers and published research on 17 October 2026.
Reviewed by the Reserve Meds clinical operations team on 17 October 2026.
Crohn's disease: the short answer
The US FDA has approved seven medicines covered on this page for Crohn's disease, each for a specific group of patients: Entyvio, Skyrizi, Tremfya, Omvoh, Stelara, Rinvoq and Humira. On 17 October 2026, seven of them were on the Saudi or Abu Dhabi register, so ask your hospital about local supply first. Where a medicine is not registered, the treating hospital can ask the national regulator to import it for one named patient. Reserve Meds is a digital health company that helps with that process. We do not diagnose or prescribe.
- US FDA-approved medicines on this page: Entyvio, Skyrizi, Tremfya, Omvoh, Stelara, Rinvoq and Humira.
- Gulf registers (checked 17 October 2026): see each medicine below.
- Legal route: local supply where listed; otherwise a named-patient import request filed by the treating hospital.
- Price: Quote on request.
What is Crohn's disease?
Crohn's disease is a chronic disease that causes inflammation in the digestive tract. It can affect any part of the digestive tract, from the mouth to the anus, but it usually affects the small intestine and the beginning of the large intestine. It is a type of inflammatory bowel disease (IBD).[1, 2]
Symptoms vary from person to person and may include diarrhea, cramping and pain in the abdomen, and weight loss. It is more likely to develop between the ages of 20 and 29. The cause is unknown; genes, abnormal immune reactions and the microbiome are thought to play a role, and smoking may double the risk.[2, 1]
Doctors treat Crohn's disease with medicines and surgery. The goal is to decrease inflammation, prevent flares and keep the disease in remission.[2]
Crohn's disease in the Gulf
Pediatric Crohn's disease in Bahrain was described in the Oman Medical Journal, and Gulf researchers have studied the effect of smoking on inflammatory bowel disease outcomes (2024).[3, 4]
We checked every medicine on this page against the full SFDA drugs list and the Abu Dhabi Department of Health drug code list on 17 October 2026. 7 of 7 were listed in Saudi Arabia and 7 of 7 in Abu Dhabi. The result for each medicine is shown below. A listing does not mean every hospital stocks the medicine, and federal UAE, Kuwait, Qatar, Bahrain and Oman registers were not checked.[5, 6]
US FDA-approved medicines for Crohn's disease
Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.
- Entyvio (vedolizumab)
US FDA-approved for adults with moderately to severely active Crohn's disease, and ulcerative colitis. It is an infusion or an injection under the skin.[7]
Current US label version: 29 April 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[5, 6]
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar - Skyrizi (risankizumab-rzaa)
US FDA-approved for adults with moderately to severely active Crohn's disease. It is an IL-23 blocker.[8]
Current US label version: 15 June 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[5, 6]
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar - Tremfya (guselkumab)
US FDA-approved for adults with moderately to severely active Crohn's disease. It is an IL-23 blocker.[9]
Current US label version: 4 June 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[5, 6]
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar - Omvoh (mirikizumab-mrkz)
US FDA-approved for adults with moderately to severely active Crohn's disease, and ulcerative colitis. It is an IL-23 blocker.[10]
Current US label version: 16 June 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[5, 6]
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar - Stelara (ustekinumab)
US FDA-approved for moderately to severely active Crohn's disease in adults and children 2 years and older. Biosimilar versions of ustekinumab exist.[11]
Current US label version: 8 September 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[5, 6]
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar - Rinvoq (upadacitinib)
US FDA-approved for adults with moderately to severely active Crohn's disease who did not respond well enough to, or could not take, one or more TNF blockers. It is a JAK inhibitor tablet.[12]
Current US label version: 30 June 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[5, 6]
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar - Humira (adalimumab)
US FDA-approved for moderately to severely active Crohn's disease in adults and children 6 years and older. It is a TNF blocker, and biosimilar versions exist.[13]
Current US label version: 23 December 2025. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[5, 6]
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar
How families in the Gulf can access treatment
If the medicine is listed in your country. Ask your specialist and the hospital about local supply first. A listing does not mean every hospital stocks the medicine, but it is usually the fastest route, and you may not need us.
If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital confirms.[14, 15] Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital.
Who does what
- Your treating specialist decides whether a medicine is right for the patient and writes the medical letter.
- The hospital checks local supply, files any import request, and gives the treatment safely.
- The national regulator decides whether to approve the import of a medicine that is not registered.
- The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
- Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.
Documents you will usually need
- A letter from the treating specialist with the diagnosis, past treatments and why this medicine is being considered
- Reports that confirm the diagnosis, such as genetic, pathology, imaging or laboratory results, translated into English where needed
- Recent clinic notes and a list of current medicines
- For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
- Proof of the US FDA approval and the US prescribing information (we can supply these)
We give you a written timeline estimate for your case before you commit. The regulator, the hospital or treatment center and the manufacturer set their own timelines.
What treatment costs
Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.
How Reserve Meds helps
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.
Ask us about treatment for Crohn's disease
Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.
Frequently asked questions
Is there an FDA-approved treatment for Crohn's disease?
Yes. The medicines on this page have US FDA approval for specific groups of patients: Entyvio, Skyrizi, Tremfya, Omvoh, Stelara, Rinvoq and Humira. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.
Is Entyvio available in Saudi Arabia or the UAE?
We checked on 17 October 2026. Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (Department of Health drug code list): listed. A listing in Abu Dhabi does not show federal UAE status, which we could not verify. Your hospital confirms current supply.
How can a family in the Gulf get Entyvio?
Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital.
How much does treatment cost?
Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.
Does Reserve Meds diagnose or prescribe?
No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or decide what a regulator approves. Your specialist and hospital make the medical decisions.
Are biosimilars an option for Crohn's disease?
Yes, where they are approved. Adalimumab and ustekinumab biosimilars are listed under several brand names in the Saudi and Abu Dhabi registers, as shown on this page. Your gastroenterologist decides which product to use.
Sources for the condition-specific answers: [5, 6]
Sources
Accessed and checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital confirms the current position before anything is filed.
- MedlinePlus (US National Library of Medicine): Crohn's Disease
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): Crohn’s Disease
- Al-Mendalawi MD, et al. Pediatric Crohn's Disease in Bahrain. Oman Med J. 2019 (PubMed 31110639)
- Alzahrani BA, et al. The effect of smoking in inflammatory bowel disease outcomes. Front Gastroenterol (Lausanne). 2024 (PubMed 41822734)
- SFDA: Drugs List, public register (all 9,173 entries checked by brand name on 17 October 2026)
- Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
- DailyMed: ENTYVIO (vedolizumab) US prescribing information, label version 29 April 2026
- DailyMed: SKYRIZI (risankizumab-rzaa) US prescribing information, label version 15 June 2026
- DailyMed: TREMFYA (guselkumab) US prescribing information, label version 4 June 2026
- DailyMed: OMVOH (mirikizumab-mrkz) US prescribing information, label version 16 June 2026
- DailyMed: STELARA (ustekinumab) US prescribing information, label version 8 September 2026
- DailyMed: RINVOQ (upadacitinib) US prescribing information, label version 30 June 2026
- DailyMed: HUMIRA (adalimumab) US prescribing information, label version 23 December 2025
- SFDA: Special Access Program (SAP) guidance, version 1.0
- NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products
Related
- Ulcerative colitis
- Ankylosing spondylitis
- Eosinophilic esophagitis (EoE)
- Entyvio: drug overview
- Skyrizi: drug overview
- Tremfya: drug overview
- Named-patient access in the Gulf, explained
- US-approved medicines not yet registered in the Gulf
- Answers to common access questions
- Cross-border disclosures
- اقرأ هذه الصفحة بالعربية
- यह पृष्ठ हिंदी में पढ़ें
- یہ صفحہ اردو میں پڑھیں
This page is general health information, not medical advice. It does not replace a consultation with your doctor.